Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL) Short Interest Update

Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL) was the target of a significant drop in short interest in the month of December. As of December 15th, there was short interest totaling 4,639 shares, a drop of 45.6% from the November 30th total of 8,520 shares. Based on an average trading volume of 42,734 shares, the short-interest ratio is currently 0.1 days. Approximately 0.0% of the shares of the company are sold short. Approximately 0.0% of the shares of the company are sold short. Based on an average trading volume of 42,734 shares, the short-interest ratio is currently 0.1 days.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Adlai Nortye in a research note on Wednesday, October 8th. One analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Reduce”.

Adlai Nortye Stock Up 7.2%

Shares of ANL stock opened at $1.64 on Friday. Adlai Nortye has a 1-year low of $0.88 and a 1-year high of $2.99. The stock’s 50-day moving average is $1.46 and its 200 day moving average is $1.57.

Adlai Nortye Company Profile

Adlai Nortye Inc (NASDAQ: ANL) is a specialty chemical manufacturer headquartered in China’s Jiangsu Province. The company focuses on the research, development, production and sale of fine chemicals, with a primary emphasis on amino acids and their derivatives.

Adlai Nortye’s product portfolio includes betaine compounds, a range of high-purity L-amino acids such as L-methionine, L-threonine and glycine, as well as various chemical intermediates. These offerings serve multiple end markets, including animal feed and nutrition, personal care and cosmetic formulations, pharmaceutical ingredients and industrial chemical processes.

The company operates multiple production facilities alongside an in-house research and development center dedicated to process innovation and quality control.